Thus, Yamamoto and coworkers designed ASOs able to target exon-1, intron-1 and exon-8 in AR pre-mRNA to knockdown both ARFL and AR-Vs: these ASOs suppress the growth of Enzalutamide-resistant prostate cancer cell lines and xenografts [630]. Here, AR is linked to prostate carcinoma.